Business Wire

375ai Launches Data Layer for the Physical World on Solana

29.10.2025 15:00:00 EET | Business Wire | Press release

Share

375ai, an edge data intelligence company transforming the physical world into structured, machine-readable insights, today announced the launch of its mainnet on Solana.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028976994/en/

375ai Launches Data Layer for the Physical World

The physical world is generating more data than ever before, but most of it is invisible. Traffic systems, advertising platforms, and governments still rely on outdated infrastructure and fragmented data sources to understand how people and goods move through cities. Centralized data pipelines are expensive, slow, and often limited to incomplete or delayed insights. Meanwhile, AI systems are hungry for real world context not just synthetic inputs. Without structured, real time data, they can’t power smarter mobility, logistics, and safety solutions.

375ai enables real world data capture, unlocking a new category of physical AI infrastructure. At launch, the network already has unique visibility into the flow of commerce, with 2 million vehicles per day observed by its 375edge devices and more than 300,000 375go mobile app downloads across 170+ countries.

Each 375edge device is equipped with high definition cameras, audio and environmental sensors, and on-device compute powered by NVIDIA. Instead of streaming terabytes of unstructured data to the cloud, these devices leverage edge AI to distill nearly terabytes of raw inputs into megabytes of insights per day. These insights fuel applications in mobility, logistics, advertising, public safety, and AI model training.

375ai is part of a new wave of decentralized infrastructure networks, or DePINs, redefining how physical infrastructure is deployed, operated, and monetized. By launching its mainnet, the company moves beyond traditional cloud based data collection toward a decentralized, user owned network where contributors are rewarded for powering real world data capture.

“Cities, enterprises, and AI systems need real time awareness of the physical world,” said Harry Dewhirst, CEO of 375ai. “Our mainnet launch turns that vision into reality, activating a global network where real world data is captured at the edge, secured by cryptography, and made available in real time to those building the future.”

375ai is led by a seasoned executive team with decades of experience in networking, cybersecurity, telecoms, digital media, and data. Alongside CEO Harry Dewhirst, the leadership team includes COO Rob Atherton, CBO Trevor Branon, and Chief AI Officer Chad Partridge. Collectively, they bring backgrounds at companies such as Juniper Networks, Palo Alto Networks, Fortinet, Linksys, Singtel, and Telefonica.

About 375ai

Founded in 2022, 375ai transforms messy, analog real-world phenomena into structured digital intelligence. By deploying AI powered edge devices across cities, 375ai makes the world machine-readable, one city at a time. Each 375edge device processes massive raw data streams locally, distilling them into actionable insights that fuel applications in advertising, logistics, public safety, economic forecasting, and beyond. With live deployments in Los Angeles and expansions underway in New York and Miami, 375ai is building the foundation for real world AI at global scale.

To learn more, visit: https://375.ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028976994/en/

Contacts

Media Contact:
Michael Gushansky
Michael@375.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye